ADTX vs. APVO, SXTC, CMRA, HSTO, BLPH, ATHX, AMPE, OBSV, EVFM, and SPRC
Should you be buying Aditxt stock or one of its competitors? The main competitors of Aditxt include Aptevo Therapeutics (APVO), China SXT Pharmaceuticals (SXTC), Comera Life Sciences (CMRA), Histogen (HSTO), Bellerophon Therapeutics (BLPH), Athersys (ATHX), Ampio Pharmaceuticals (AMPE), ObsEva (OBSV), Evofem Biosciences (EVFM), and SciSparc (SPRC). These companies are all part of the "pharmaceutical preparations" industry.
Aditxt (NASDAQ:ADTX) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, community ranking, valuation, media sentiment, institutional ownership, risk, earnings and dividends.
Aptevo Therapeutics has higher revenue and earnings than Aditxt.
In the previous week, Aditxt had 1 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 3 mentions for Aditxt and 2 mentions for Aptevo Therapeutics. Aptevo Therapeutics' average media sentiment score of 0.30 beat Aditxt's score of 0.21 indicating that Aptevo Therapeutics is being referred to more favorably in the news media.
Aptevo Therapeutics has a net margin of 0.00% compared to Aditxt's net margin of -5,016.31%. Aptevo Therapeutics' return on equity of -112.27% beat Aditxt's return on equity.
Aptevo Therapeutics received 194 more outperform votes than Aditxt when rated by MarketBeat users. Likewise, 52.66% of users gave Aptevo Therapeutics an outperform vote while only 44.44% of users gave Aditxt an outperform vote.
Aditxt has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Comparatively, Aptevo Therapeutics has a beta of 5.13, meaning that its share price is 413% more volatile than the S&P 500.
Aditxt presently has a consensus target price of $61.00, indicating a potential upside of 2,890.20%. Given Aditxt's higher probable upside, research analysts plainly believe Aditxt is more favorable than Aptevo Therapeutics.
15.5% of Aditxt shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 1.2% of Aditxt shares are owned by insiders. Comparatively, 0.3% of Aptevo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Aptevo Therapeutics beats Aditxt on 9 of the 14 factors compared between the two stocks.
Get Aditxt News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
